Hirschsprung disease-ganglioneuroblastoma syndrome

Hirschsprung disease-ganglioneuroblastoma syndrome is an extremely rare condition characterized by the co-occurrence of Hirschsprung disease (HSCR) and ganglioneuroblastoma, a tumor arising from neural crest-derived cells. Hirschsprung disease is a congenital disorder of the gastrointestinal tract in which ganglion cells are absent from a segment of the bowel (aganglionosis), leading to functional intestinal obstruction, severe constipation, abdominal distension, and potentially life-threatening enterocolitis. Ganglioneuroblastoma is a neuroblastic tumor of the sympathetic nervous system that can arise in the adrenal glands, retroperitoneum, or other sites along the sympathetic chain. Both conditions share a common embryological origin in neural crest cells, which are precursors to enteric ganglia and sympathetic nervous system components. The association between Hirschsprung disease and neural crest-derived tumors such as ganglioneuroblastoma or neuroblastoma has been reported in a small number of cases in the medical literature. This co-occurrence supports the hypothesis that a defect in neural crest cell migration, differentiation, or proliferation may underlie both conditions. Mutations in the RET proto-oncogene have been implicated in some cases, as RET plays a critical role in neural crest development and is known to be associated with both Hirschsprung disease and certain neural crest tumors. Treatment is directed at each component of the syndrome. Hirschsprung disease is managed surgically through pull-through procedures to remove the aganglionic bowel segment and restore intestinal continuity. Ganglioneuroblastoma treatment depends on the stage, histological subtype, and risk stratification, and may include surgical resection, chemotherapy, and in some cases radiation therapy. Long-term follow-up is essential for monitoring bowel function, nutritional status, and tumor recurrence. Given the rarity of this syndrome, management is best coordinated by a multidisciplinary team including pediatric surgeons, oncologists, and geneticists.

Common questions about Hirschsprung disease-ganglioneuroblastoma syndrome